Sugi Predict

Sugi Predict / Compounds / SCHEMBL2462980

SCHEMBL2462980

SCHEMBL2462980

CC(C)COC(=O)C1(C(N)=O)CCC(C2=C3C=NC=C[N+]3(N)C(c3cccc(OCc4ccccc4)c3)=N2)CC1

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 2/20 0.33
▸ IGF1R P08069 3/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ BTK Q06187 1/20 0.32
▸ JAK2 O60674 2/20 0.31
▸ JAK3 P52333 1/20 0.31
▸ CTSK P43235 1/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ SLC16A3 O15427 1/20 0.31
▸ SLC16A1 P53985 1/20 0.31
▸ MCTS1 Q9ULC4 1/20 0.31
▸ PPARG P37231 1/20 0.31
▸ PPARA Q07869 1/20 0.31
▸ SPHK1 Q9NYA1 1/20 0.31
▸ DHODH Q02127 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460247 0.92 JAK2 (0.37) ADAM17IGF1RKCNH2BTKJAK2
SCHEMBL2460657 0.91 ADAM17 (0.39) ADAM17IGF1RKCNH2BTKJAK2
SCHEMBL2457720 0.83 IGF1R (0.34) ADAM17IGF1RKCNH2BTKJAK2
SCHEMBL2460551 0.82 IGF1R (0.48) IGF1RKCNH2BTKJAK2JAK1
SCHEMBL2462745 0.81 IGF1R (0.34) ADAM17IGF1RKCNH2BTKJAK2
SCHEMBL2457199 0.81 IGF1R (0.34) ADAM17IGF1RKCNH2BTKJAK2
SCHEMBL5115303 0.81 IGF1R (0.35) ADAM17IGF1RKCNH2BTKJAK2
SCHEMBL2457743 0.81 KDM4E (0.34) IGF1RKCNH2BTKSPHK1
SCHEMBL2460164 0.81 ACACB (0.35) ADAM17IGF1RJAK2JAK1
SCHEMBL2457374 0.81 IGF1R (0.43) IGF1RKCNH2JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 ADAM17 3188/4885IGF1R 1/4885KCNH2 1921/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 ADAM17 3188/4885IGF1R 1/4885KCNH2 1921/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 ADAM17 3188/4885IGF1R 1/4885KCNH2 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.